This mechanistic synergy, wherein mTOR suppression activates autophagy to clear pathogenic proteins, establishes the molecular basis for isoacteoside’s efficacy in mitigating both the Aβ plaque burden and the cognitive deficits in AD models. This evidence concerns the gene MTOR and Alzheimer disease.